197 related articles for article (PubMed ID: 37182571)
1. Exacerbation of Chronic Spontaneous Urticaria Following Coronavirus Disease 2019 (COVID-19) Vaccination in Omalizumab-Treated Patients.
Lee JH; Shin E; Kim HK; Song WJ; Kwon HS; Kim TB; Cho YS
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2403-2410. PubMed ID: 37182571
[TBL] [Abstract][Full Text] [Related]
2. Urticaria relapse after mRNA COVID-19 vaccines in patients affected by chronic spontaneous urticaria and treated with antihistamines plus omalizumab: A single-center experience.
Picone V; Napolitano M; Martora F; Guerriero L; Fabbrocini G; Patruno C
Dermatol Ther; 2022 Nov; 35(11):e15838. PubMed ID: 36109351
[TBL] [Abstract][Full Text] [Related]
3. Retrospective evaluation of patients with chronic spontaneous urticaria using omalizumab during the COVID-19 pandemic.
Koç Yıldırım S; Demirel Öğüt N; Erbağcı E
J Cosmet Dermatol; 2022 Feb; 21(2):431-434. PubMed ID: 34982508
[TBL] [Abstract][Full Text] [Related]
4. Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: Results of the UCARE COVAC-CU study.
Kocatürk E; Salameh P; Sarac E; Vera Ayala CE; Thomsen SF; Zuberbier T; Ensina LF; Popov TA; van Doorn MBA; Giménez-Arnau AM; Asero R; Criado PR; Aarestrup FM; AbdulHameed Ansari Z; Al Abri S; Al-Ahmad M; Al Hinai B; Allenova A; Al-Nesf M; Altrichter S; Arnaout R; Bartosińska J; Bauer A; Bernstein JA; Bizjak M; Bonnekoh H; Bouillet L; Brzoza Z; Calvalcanti Dela Bianca Melo AC; Campinhos FL; Carne E; Purayil SC; Cherrez-Ojeda I; Chong-Neto HJ; Christoff G; Conlon N; Jardim Criado RF; Cvenkel K; Damadoglu E; Danilycheva I; Day C; de Montjoye L; Demir S; Ferucci SM; Fomina D; Fukunaga A; Garcia E; Gelincik A; Göbel JH; Godse K; Gonçalo M; Gotua M; Grattan C; Gugala A; Guillet C; Kalyoncu AF; Karakaya G; Kasperska-Zając A; Katelaris CH; Khoshkhui M; Kleinheinz A; Kolacinska-Flont M; Kolkhir P; Košnik M; Krasowska D; Kumaran MS; Kuprys-Lipinska I; Kurowski M; Kuznetsova EV; Larenas-Linnemann D; Lebedkina MS; Lee Y; Makris M; Gómez RM; Nasr I; Neisinger S; Oda Y; Kara RÖ; Palitot EB; Papapostolou N; Salvador Parisi CA; Pesque D; Peter J; Petkova E; Ridge K; Rudenko M; Rutkowski K; Saini SS; Salman A; Sanchez J; Şekerel B; Serdotetskova SA; Serpa FS; Dikicier BS; Sidiropoulos N; Sikora A; Sørensen JA; Soria A; Kucuk OS; Thalappil SR; Tomaszewska K; Tuncay G; Unal D; Valle S; van Lindonk E; Vestergaard C; Meshkova RY; Vitchuk A; Xepapadaki P; Ye YM; Zalewska-Janowska A; Zamlynski M; Maurer M
J Allergy Clin Immunol; 2023 Nov; 152(5):1095-1106. PubMed ID: 37574079
[TBL] [Abstract][Full Text] [Related]
5. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.
Foti C; Romita P; Ambrogio F; Fanelli M; Panebianco R; Vena GA; Cassano N; Ragusa M; Giuffrida R; Papaianni V; Borgia F; Cannavò SP; Guarneri F
Dermatol Ther; 2022 Feb; 35(2):e15248. PubMed ID: 34877757
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria.
; Yu R; Qian W; Zheng Q; Xiong J; Chen S; Chen A; Chen J; Fang S; Huang K; Cai T
Int Arch Allergy Immunol; 2023; 184(7):643-655. PubMed ID: 36996780
[TBL] [Abstract][Full Text] [Related]
7. The effect of COVID-19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: A cross-sectional, comparative study.
Bostan E; Zaid F; Karaduman A; Dogan S; Gulseren D; Yalici-Armagan B; Akdogan N; Ersoy-Evans S; Elcin G
J Cosmet Dermatol; 2021 Nov; 20(11):3369-3375. PubMed ID: 34599630
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Hydroxychloroquine and Omalizumab in Chronic Spontaneous Urticaria: A Real-World Study.
Khan N; Epstein TG; DuBuske I; Strobel M; Bernstein DI
J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3300-3305. PubMed ID: 36115542
[TBL] [Abstract][Full Text] [Related]
9. Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: A post-marketing surveillance study.
Hide M; Fukunaga A; Suzuki T; Nakamura N; Kimura M; Sasajima T; Kiriyama J; Igarashi A
Allergol Int; 2023 Apr; 72(2):286-296. PubMed ID: 36272899
[TBL] [Abstract][Full Text] [Related]
10. Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta-analysis.
He ZH; Qiu SC; Huang ZW; Zhang GQ; An QQ; Qu F; Wang N
Dermatol Ther; 2022 Dec; 35(12):e15928. PubMed ID: 36222320
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
Johal KJ; Chichester KL; Oliver ET; Devine KC; Bieneman AP; Schroeder JT; MacGlashan DW; Saini SS
J Allergy Clin Immunol; 2021 Jun; 147(6):2271-2280.e8. PubMed ID: 33713769
[TBL] [Abstract][Full Text] [Related]
13. Relapse or worsening of chronic spontaneous urticaria during SARS-CoV-2 infection and vaccination in children: A telemedicine follow-up.
Lascialfari G; Sarti L; Barni S; Liccioli G; Paladini E; Guarnieri V; Ricci S; Giovannini M; Mori F
Allergol Immunopathol (Madr); 2022; 50(S Pt 2):1-7. PubMed ID: 36156167
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.
Metz M; Vadasz Z; Kocatürk E; Giménez-Arnau AM
Clin Rev Allergy Immunol; 2020 Aug; 59(1):38-45. PubMed ID: 32418171
[TBL] [Abstract][Full Text] [Related]
15. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
[TBL] [Abstract][Full Text] [Related]
16. Clinical and laboratory parameters associated with treatment response to third-line therapies in chronic refractory urticaria: A real world study from northern India.
Mehta H; Bishnoi A; Parsad D; Kumaran MS
Dermatol Ther; 2022 Nov; 35(11):e15887. PubMed ID: 36181400
[TBL] [Abstract][Full Text] [Related]
17. Impact of COVID-19 pandemic on the course of refractory chronic spontaneous urticaria under omalizumab treatment.
Olgaç M; Yeğit OO; Beyaz Ş; Öztop N; Tüzer C; Eyice D; Karadağ P; Coşkun R; Demir S; Çolakoğlu B; Büyüköztürk S; Gelincik A
An Bras Dermatol; 2023; 98(2):189-197. PubMed ID: 36609081
[TBL] [Abstract][Full Text] [Related]
18. Patients With Chronic Spontaneous Urticaria Who Have Wheals, Angioedema, or Both, Differ Demographically, Clinically, and in Response to Treatment-Results From CURE.
Buttgereit T; Vera C; Aulenbacher F; Church MK; Hawro T; Asero R; Bauer A; Bizjak M; Bouillet L; Dissemond J; Fomina D; Giménez-Arnau AM; Grattan C; Gregoriou S; Kulthanan K; Kasperska-Zajac A; Kocatürk E; Makris M; Kolkhir P; Weller K; Magerl M; Maurer M
J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3515-3525.e4. PubMed ID: 37604426
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors of recurrence after omalizumab cessation in the elderly with urticaria: A real-life study.
Oztop N; Demir S; Unal D; Beyaz S; Terzioglu K; Olgac M; Gelincik A
Allergy Asthma Proc; 2022 Nov; 43(6):519-528. PubMed ID: 36335414
[No Abstract] [Full Text] [Related]
20. How to Treat Patients with Chronic Spontaneous Urticaria with Omalizumab: Questions and Answers.
Türk M; Carneiro-Leão L; Kolkhir P; Bonnekoh H; Buttgereit T; Maurer M
J Allergy Clin Immunol Pract; 2020 Jan; 8(1):113-124. PubMed ID: 31374358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
